Dr. Mary L. Schmidt
Claim this profileUniversity of Illinois
Expert in Cancer
Expert in Neuroblastoma
48 reported clinical trials
99 drugs studied
About Mary L. Schmidt
Education:
- Graduated from the University of Louisville School of Medicine.
- Completed Residency and Fellowship at Northwestern University.
Experience:
- Holds Board Certifications from the American Board of Pediatrics and the American Board of Hematology-Oncology.
- Specializes in Pediatric Hematology and Oncology with a focus on Hemangioma, palliative care, and vascular formations.
- Has over 30 years of experience practicing at UI Health (University of Illinois Hospital & Health Sciences System).
- Fluent in multiple languages, including Spanish.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Neuroblastoma
Global LeaderMYC positive
Stage IV
MYC negative
Affiliated Hospitals
Clinical Trials Mary L. Schmidt is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Mary L. Schmidt
Clinical Trial Related8 years of experience running clinical trials · Led 48 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Mary L. Schmidt has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Laboratory Biomarker Analysis
- Vincristine Sulfate
- Cytology Specimen Collection Procedure
Breakdown of trials Mary L. Schmidt has run
Cancer
Neuroblastoma
Brain Tumor
Rhabdomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mary L. Schmidt specialize in?
Mary L. Schmidt focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Mary L. Schmidt currently recruiting for clinical trials?
Yes, Mary L. Schmidt is currently recruiting for 15 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Mary L. Schmidt has studied deeply?
Yes, Mary L. Schmidt has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Mary L. Schmidt?
Apply for one of the trials that Mary L. Schmidt is conducting.
What is the office address of Mary L. Schmidt?
The office of Mary L. Schmidt is located at: University of Illinois, Chicago, Illinois 60612 United States. This is the address for their practice at the University of Illinois.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.